Comparison
Ipamorelin vs. Liraglutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
170851-70-4
204656-20-2
Molecular weight
711.86 g/mol
3751 g/mol
Half-life
2 h
13 h
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGMechanism of action
Ipamorelin
Ipamorelin is a selective agonist at the GH secretagogue receptor (GHSR-1a). Compared to GHRP-2 and GHRP-6 its selectivity for the growth-hormone axis is higher; ACTH, cortisol and prolactin are not significantly stimulated in clinical studies. This selectivity was the main reason for its development over older GHRPs.
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
5
of which in humans
3
4
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
1